Preclinical News and Research

RSS

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of remote monitoring technologies today announced the market release of the TactiCath catheter. The TactiCath catheter, an Endosense company product, is an irrigated RF contact force ablation catheter with features that offer a major advance in ablation therapy for patients with cardiac arrhythmias and particularly Atrial Fibrillation (AF).

11 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.

10 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

MicroStockProfit.com releases NexMed investment report

MicroStockProfit.com announces an investment report featuring NexMed Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 May 2010

Two-day symposium on molecular neuroimaging

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Preclinical News and Research

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Bovie Medical first-quarter revenues decrease to $5.6M

Immunomedics third-quarter revenues increase to $10.7 million

Achillion reports lower net loss of $5.6M for first-quarter 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

MicroStockProfit.com releases NexMed investment report

Two-day symposium on molecular neuroimaging

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Tel Aviv researchers develop microscope-based cell scanner to speed research into fat-busting drugs

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Curis reports net income of $4.8M for first-quarter 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News